Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy.
about
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert groupDrug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry StudyOutcome and survival of asymptomatic PML in natalizumab-treated MS patients.Immunological Markers for PML Prediction in MS Patients Treated with NatalizumabMonoclonal antibodies as disease modifying therapy in multiple sclerosis.Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.45 years after the discovery of human polyomaviruses BK and JC: Time to speed up the understanding of associated diseases and treatment approaches.Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.A case of posterior reversible encephalopathy syndrome associated with gilenya(®) (fingolimod) treatment for multiple sclerosis.MRI pattern in asymptomatic natalizumab-associated PML.Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?
P2860
Q26780412-773F741E-0823-430D-8D37-669D165927BEQ30815289-1F92FE7E-7853-4671-9D49-C619083132F9Q33810020-A45DC270-3BFD-4865-AFDF-F42EDCE01C72Q34562841-55094825-A232-4522-8540-4F2011519A19Q34818048-BC507D4B-70D8-493C-91AF-D6AEA88FCD95Q37668086-F7AD6060-FFE2-4DA5-A906-E82C844EADC1Q38167347-646A2E54-8EEA-42FD-B989-C310820A9E8FQ38172961-AE64D08B-70E2-4C5D-B859-C1E893ECA59EQ38801394-B7A96CD5-5894-4F96-8872-4ED174BCD5A9Q39211049-15A98167-F679-4260-9999-178B003E5980Q40619670-59084AB6-C179-47DF-868E-8B41C4479C14Q41126166-E44A88B2-A3A7-4214-958C-6BFF825A6D9BQ41411445-FFF63D8C-7050-44B1-A155-628BB3BCB586Q41745436-FDBE1935-C32F-4070-9CF2-839B436581C4Q42226607-AD47C03E-5B0D-4DBB-A74B-D7AA7465441F
P2860
Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Presymptomatic diagnosis with ...... ultifocal leukoencephalopathy.
@en
type
label
Presymptomatic diagnosis with ...... ultifocal leukoencephalopathy.
@en
prefLabel
Presymptomatic diagnosis with ...... ultifocal leukoencephalopathy.
@en
P2860
P356
P1476
Presymptomatic diagnosis with ...... ultifocal leukoencephalopathy.
@en
P2093
Anders von Heijne
Hans Lindå
P2860
P356
10.3389/FNEUR.2013.00011
P577
2013-02-18T00:00:00Z